Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2023;34(1):78-85
Article Links
Tocilizumab in the Treatment of Eosinophilic Fasciitis: A Case Study and Review of Literature
Sarah El Iskandarani1, Maya Khasho2, Mira Merashli3
Authors Information

1Memorial Sloan Kettering Cancer Centre, Integrative Medicine Service, New York City, New York, USA

2 Tishreen University, Faculty of Medicine, Latakia, Syria

3 American University of Beirut, Department of Internal Medicine, Division of Rheumatology, Beirut, Lebanon

S El Iskandarani, M Khasho, M Merashli

Keywords: eosinophilic fasciitis, Shulman’s disease, tocilizumab
References
  1. Shulman L. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 1975;88:70-86.
  2. Doyle JA, Ginsburg WW. Eosinophilic fasciitis. Med Clin North Am 1989;73:1157-66.
  3. Lebeaux D, Francès C, Barete S, et al. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology 2012;51:557-61.
  4. Pinal-Fernandez I, Selva-O'Callaghan A, Grau J. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 2014;13:379-82.
  5. Kähäri V-M, Heino J, Niskanen L, Fräki J, Uitto J. Eosinophilic fasciitis: increased collagen production and type I procollagen messenger RNA levels in fibroblasts cultured from involved skin. Arch Dermatol 1990;126:613-7.
  6. Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K. Serum levels of tissue inhibitor of metalloproteinase‐1 and 2 in patients with eosinophilic fasciitis. Br J Dermatol 2004;151:407-12.
  7. Falanga V, Medsger Jr TA. Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. J Am Acad Dermatol 1987;17:648-56.
  8. Hur J-W, Lee H-S, Uhm W-S, et al. Eosinophilic fasciitis associated with autoimmune thyroiditis. Korean J Intern Med 2005;20:180.
  9. Seibold JR, Rodnan GP, Medsger Jr TA, Winkelstein A. Circulating immune complexes in eosinophilic fasciitis. Arthritis Rheum 1982;25:1180-5.
  10. Kent LT, Cramer SF, Moskowitz RW. Eosinophilic fasciitis. Arthritis  Rheum 1981;24:677-83.
  11. Urzal J, Cimbron M, Mendonça T, Farinha F. Eosinophilic fasciitis (Shulman’s disease): review and comparative evaluation of seven patients. Reumatologia 2019;57:85.
  12. Ihn H. Eosinophilic fasciitis: From pathophysiology to treatment. Allergol Int 2019;68:437-9.
  13. Fett N, Arthur M. Eosinophilic fasciitis: current concepts. Clin Dermatol 2018;36:487-97.
  14. Mertens JS, Seyger MM, Thurlings RM, Radstake TR, de Jong EM. Morphea and eosinophilic fasciitis: an update. Am J Clin Dermatol 2017;18:491-512.
  15. Mortezavi M, Barrett M, Edrissian M. Successful treatment of refractory eosinophilic fasciitis with reslizumab. JAAD Case Rep 2020;6:951-3.
  16. Killen J, Swift G, White R. Eosinophilic fasciitis with pulmonary and pleural involvement. Postgraduate medical journal 2000;76:36-7.
  17. Rizzo S. Eosinophilic pleuropericarditis and fasciitis. A new case. Monaldi Arch Chest Dis 2002;57:311-3.
  18. Kirschstein M, Helmchen U, Jensen R, Küster R, Lehmann H. Kidney involvement in a 17-year-old boy with eosinophilic fasciitis. Clin Nephrol 1999;52:183-7.
  19. Hughes M, Pauling JD, Armstrong-James L, Denton CP, Galdas P, Flurey C. Gender-related differences in systemic sclerosis. Autoimmun Rev 2020;19:102494.
  20. Shulman LE. The eosinophilia-myalgia syndrome associated with ingestion of smallcap˜ L-tryptophan. Arthritis Rheum 1990;33:913-7.
  21. Mazori DR, Femia AN, Vleugels RA. Eosinophilic fasciitis: an updated review on diagnosis and treatment. Curr Rheumatol Rep 2017;19:1-12.
  22. Dybowski F, Neuen-Jacob E, Braun J. Eosinophilic fasciitis and myositis: use of imaging modalities for diagnosis and monitoring. Ann Rheum Dis 2008;67:572-4.
  23. Cheriet S, Chastan M, Levesque H, Marie I. Positron emission tomography in the diagnosis of eosinophilic fasciitis. QJM 2011;104:987-8.
  24. Jinnin M, Yamamoto T, Asano Y, Ishikawa O, Sato S, Takehara K, et al. Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. J Dermatol 2018;45:881-90.
  25. Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol 2008;47:29-35.
  26. Thomson G, Johnston J, Thomson B. Eosinophilic fasciitis treated with tocilizumab: demonstration of efficacy after withdrawal and re-challenge in a patient. J Rheum Dis Treat 2015;1:021.
  27. Pinheiro G, Costa AR, Campar A, Mendonça T. Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports. Eur J Case Rep Intern Med 2020;7.
  28. Tull R, Hoover III WD, De Luca JF, Huang WW, Jorizzo JL. Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission. Drugs Context 2018;7.
  29. Loupasakis K, Derk CT. Eosinophilic fasciitis in a pediatric patient. JCR 2010;16:129-31.
  30. Fleming C, Clarke P, Kemmett D. Eosinophilic fasciitis with myelodysplasia responsive to treatment with cyclosporin. Br J Dermatol 1997;136:297-8.
  31. Alonso-Castro L, de las Heras E, Moreno C, Fleta-Asín B, Muñoz-Zato E, Carrillo R, et al. Eosinophilic fasciitis/generalized morphea overlap successfully treated with azathioprine. Int J Dermatol 2014;53:1386-8.
  32. Caspi D, Fishel R, Varon M, Yona E, Baratz M, Yaron M. MULTISYSTEM PRESENTATIONOF EOSINOPHILIC FASCIITIS. Rheumatology 1982;21:218-21.
  33. Scheinberg M, Hamerschlak N, Kutner J, Ribeiro AA, Ferreira E, Goldenberg J, et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol 2006;24:65.
  34. de Masson A, Bouaziz J-D, de Latour RP, Benhamou Y, Moluçon-Chabrot C, Bay JO, et al. Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature. Medicine 2013;92:69.
  35. Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Rep 2018;4:443.
  36. Espinoza F, Jorgensen C, Pers Y-M. Efficacy of Tocilizumab in the treatment of Eosinophilic fasciitis: Report of one case. Joint Bone Spine 2015;82:460-1.
  37. Vílchez-Oya F, Sánchez-Schmidt JM, Agustí A, Pros A. The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review. Clin Rheumatol 2020:1-6.
  38. Alten R, Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med 2013;45:357-63.
  39. Viallard J-F, Taupin J-L, Ranchin V, Leng B, Pellegrin J-L, Moreau J-F. Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol 2001;28:75-80.
  40. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010;49:2408-12.
  41. Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013;72:1217-20.